Literature DB >> 25056659

Human buccal epithelium acquires microbial hyporesponsiveness at birth, a role for secretory leukocyte protease inhibitor.

Celia L Menckeberg1, Jeroen Hol2, Ytje Simons-Oosterhuis1, H Rolien C Raatgeep1, Lilian F de Ruiter3, Dicky J Lindenbergh-Kortleve1, Anita M Korteland-van Male1, Sahar El Aidy4, Pieter P E van Lierop1, Michiel Kleerebezem5, Michael Groeneweg6, Georg Kraal7, Beatrix E Elink-Schuurman8, Johan C de Jongste8, Edward E S Nieuwenhuis9, Janneke N Samsom1.   

Abstract

OBJECTIVE: Repetitive interaction with microbial stimuli renders epithelial cells (ECs) hyporesponsive to microbial stimulation. Previously, we have reported that buccal ECs from a subset of paediatric patients with Crohn's disease are not hyporesponsive and spontaneously released chemokines. We now aimed to identify kinetics and mechanisms of acquisition of hyporesponsiveness to microbial stimulation using primary human buccal epithelium.
DESIGN: Buccal ECs collected directly after birth and in later stages of life were investigated. Chemokine release and regulatory signalling pathways were studied using primary buccal ECs and the buccal EC line TR146. Findings were extended to the intestinal mucosa using murine model systems.
RESULTS: Directly after birth, primary human buccal ECs spontaneously produced the chemokine CXCL-8 and were responsive to microbial stimuli. Within the first weeks of life, these ECs attained hyporesponsiveness, associated with inactivation of the NF-κB pathway and upregulation of the novel NF-κB inhibitor SLPI but no other known NF-κB inhibitors. SLPI protein was abundant in the cytoplasm and the nucleus of hyporesponsive buccal ECs. Knock-down of SLPI in TR146-buccal ECs induced loss of hyporesponsiveness with increased NF-κB activation and subsequent chemokine release. This regulatory mechanism extended to the intestine, as colonisation of germfree mice elicited SLPI expression in small intestine and colon. Moreover, SLPI-deficient mice had increased chemokine expression in small intestinal and colonic ECs.
CONCLUSIONS: We identify SLPI as a new player in acquisition of microbial hyporesponsiveness by buccal and intestinal epithelium in the first weeks after microbial colonisation. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Bacterial Interactions; Epithelial Cells; Gut Immunology; IBD Basic Research

Mesh:

Substances:

Year:  2014        PMID: 25056659     DOI: 10.1136/gutjnl-2013-306149

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  9 in total

Review 1.  Neonatal mucosal immunology.

Authors:  N Torow; B J Marsland; M W Hornef; E S Gollwitzer
Journal:  Mucosal Immunol       Date:  2016-09-21       Impact factor: 7.313

2.  High expression of secretory leukocyte protease inhibitor (SLPI) in stage III micro-satellite stable colorectal cancer is associated with reduced disease recurrence.

Authors:  Sandrine Nugteren; Sjoerd H den Uil; Pien M Delis-van Diemen; Ytje Simons-Oosterhuis; Dicky J Lindenbergh-Kortleve; Daniëlle H van Haaften; Hein B A C Stockmann; Joyce Sanders; Gerrit A Meijer; Remond J A Fijneman; Janneke N Samsom
Journal:  Sci Rep       Date:  2022-07-16       Impact factor: 4.996

3.  Gut microbiota facilitates dietary heme-induced epithelial hyperproliferation by opening the mucus barrier in colon.

Authors:  Noortje Ijssennagger; Clara Belzer; Guido J Hooiveld; Jan Dekker; Saskia W C van Mil; Michael Müller; Michiel Kleerebezem; Roelof van der Meer
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-27       Impact factor: 11.205

4.  Secretory leukocyte protease inhibitor regulates human periodontal ligament cell production of pro-inflammatory cytokines.

Authors:  Daniel Svensson; Alexandra Aidoukovitch; Emma Anders; Daniel Jönsson; Daniel Nebel; Bengt-Olof Nilsson
Journal:  Inflamm Res       Date:  2017-06-08       Impact factor: 4.575

5.  Secretory leukocyte protease inhibitor suppresses HPV E6-expressing HNSCC progression by mediating NF-κB and Akt pathways.

Authors:  Yu Jin; Yuexiu Li; Xin Wang; Ya Yang
Journal:  Cancer Cell Int       Date:  2019-08-23       Impact factor: 5.722

6.  Human milk extracellular vesicles target nodes in interconnected signalling pathways that enhance oral epithelial barrier function and dampen immune responses.

Authors:  Marijke I Zonneveld; Martijn J C van Herwijnen; Marcela M Fernandez-Gutierrez; Alberta Giovanazzi; Anne Marit de Groot; Marije Kleinjan; Toni M M van Capel; Alice J A M Sijts; Leonie S Taams; Johan Garssen; Esther C de Jong; Michiel Kleerebezem; Esther N M Nolte-'t Hoen; Frank A Redegeld; Marca H M Wauben
Journal:  J Extracell Vesicles       Date:  2021-03-10

7.  Ileum Gene Expression in Response to Acute Systemic Inflammation in Mice Chronically Fed Ethanol: Beneficial Effects of Elevated Tissue n-3 PUFAs.

Authors:  Josiah E Hardesty; Jeffrey B Warner; Ying L Song; Eric C Rouchka; Craig J McClain; Dennis R Warner; Irina A Kirpich
Journal:  Int J Mol Sci       Date:  2021-02-04       Impact factor: 5.923

8.  Expression of the immune modulator secretory leukocyte protease inhibitor (SLPI) in colorectal cancer liver metastases and matched primary tumors is associated with a poorer prognosis.

Authors:  Sandrine Nugteren; Jeroen A C M Goos; Pien M Delis-van Diemen; Ytje Simons-Oosterhuis; Dicky J Lindenbergh-Kortleve; Daniëlle H van Haaften; Joyce Sanders; Gerrit A Meijer; Remond J A Fijneman; Janneke N Samsom
Journal:  Oncoimmunology       Date:  2020-10-13       Impact factor: 8.110

Review 9.  Host Factors of Favorable Intestinal Microbial Colonization.

Authors:  Sabine Pirr; Dorothee Viemann
Journal:  Front Immunol       Date:  2020-10-07       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.